# To Evaluate the Beneficial Effect of Probiotics on NAFLD Patients and the Role of Gut Microbiota Modulation

> **NCT05402449** · NA · COMPLETED · sponsor: **GenMont Biotech Incorporation** · enrollment: 70 (actual)

## Conditions studied

- Non-Alcoholic Fatty Liver Disease

## Interventions

- **OTHER:** Placebo
- **DIETARY_SUPPLEMENT:** Probiotics

## Key facts

- **NCT ID:** NCT05402449
- **Lead sponsor:** GenMont Biotech Incorporation
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-14
- **Primary completion:** 2024-05-31
- **Final completion:** 2024-05-31
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2024-07-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05402449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05402449, "To Evaluate the Beneficial Effect of Probiotics on NAFLD Patients and the Role of Gut Microbiota Modulation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05402449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*